Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091501 | 1.00 | TP53 (0.45) | TP53KIF11TAAR1POLBTLR7 | |
| SCHEMBL4105415 | 0.90 | TP53 (0.46) | TP53TAAR1POLBMAPTHDAC6 | |
| SCHEMBL4789503 | 0.90 | TP53 (0.49) | TP53TAAR1POLBMAPTHDAC6 | |
| SCHEMBL13741951 | 0.88 | TP53 (0.49) | TP53TAAR1POLBMAPTHDAC6 | |
| SCHEMBL13742387 | 0.83 | TP53 (0.46) | TP53TAAR1POLBMAPTHDAC6 | |
| SCHEMBL4102093 | 0.83 | KIF11 (0.46) | KIF11TLR7MAPTKMT2ANPSR1 | |
| SCHEMBL13956802 | 0.82 | KIF11 (0.46) | KIF11TLR7MAPTNPSR1 | |
| SCHEMBL5107451 | 0.82 | KIF11 (0.47) | KIF11TLR7 | |
| SCHEMBL5647214 | 0.81 | KIF11 (0.48) | KIF11 | |
| SCHEMBL5650348 | 0.81 | KIF11 (0.48) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090214529-A9 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-08-27 | — | — | US | disclosed |
| US-20090214529-A9 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-08-27 | — | — | US | disclosed |
| WO-2008147852-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-04 | — | — | WO | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214529-A9 | KINESIN INHIBITORS | KIF5B, KIF5A, KIF5C | TP53 3779/4885KIF11 9/4885TAAR1 4666/4885 |
| US-20080292626-A1 | KINESIN INHIBITORS | KIF5B, KIF5A, KIF5C | TP53 3779/4885KIF11 9/4885TAAR1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.